Deutsche Märkte geschlossen

Revvity, Inc. (0KHE.L)

LSE - LSE Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
105,47+0,55 (+0,52%)
Börsenschluss: 04:58PM GMT

Revvity, Inc.

940 Winter Street
Waltham, MA 02451
United States
781 663 6900
https://www.revvity.com

Sektor(en)
Branche
Vollzeitmitarbeiter11.500

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Prahlad R. Singh Ph.D.CEO, President & Director1,43MN/A1965
Mr. Maxwell KrakowiakSenior VP & CFO631,11kN/A1990
Mr. Tajinder S. VohraSenior Vice President of Global Operations574,08kN/A1966
Mr. Joel S. GoldbergSenior VP of Administration, General Counsel & Secretary720,74kN/A1969
Ms. Miriame VictorSenior VP & Chief Commercial Officer555,4kN/A1982
Mr. Andrew OkunVP, Chief Accounting Officer & TreasurerN/AN/A1970
Mr. Arvind Sundar-RajanVice President of Digital & TechnologyN/AN/AN/A
Ms. Madhuri Hegde FACMG, Ph.D.Senior VP & Chief Scientific OfficerN/AN/AN/A
Ms. Jayashree ThackerSenior VP & Global Chief Information OfficerN/AN/AN/A
Mr. Stephen Barr WilloughbySenior VP of Investor Relations & Head of ESGN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Revvity, Inc.s ISS Governance QualityScore, Stand 1. März 2024, lautet 8. Die grundlegenden Scores sind Audit: 10, Vorstand: 3, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.